title: Association of methionine synthase rs1801394 and methionine synthase reductase rs1805087 polymorphisms with meningioma in adults: A meta-analysis.
abstract: Several epidemiological studies suggested that methionine synthase (MTRR) rs1801394 and methionine synthase reductase (MTR) rs1805087 polymorphisms may be involved in the risk of meningioma in adults; however, the results from different case-control studies have been inconsistent. Therefore, we performed a meta-analysis to investigate the association of MTRR and MTR polymorphisms with meningioma. PubMed, Web of Knowledge, China National Knowledge Infrastructure and Wanfang databases were searched up to October 30, 2013 and 3 publications, involving 7 case-control studies, were finally included. Following data extraction, a meta-analysis was conducted using Stata 12.0 software. The pooled results based on the fixed effects model demonstrated that the MTRR rs1801394 polymorphism was associated with an increased risk of meningioma [odds ratio (OR)=1.18, 95% confidence interval (CI): 1.05-1.32 for G vs. A; OR=1.41, 95% CI: 1.12-1.77 for GG vs. AA; OR=1.08, 95% CI: 0.94-1.33 for AG vs. AA; OR=1.19, 95% CI: 1.01-1.40 for (AG+GG) vs. AA; and OR=1.32, 95% CI: 1.07-1.63 for GG vs. (AG+AA)]; however, an association between the MTR rs1805087 polymorphism and the risk of meningioma was not identified [OR=0.99, 95% CI: 0.88-1.12 for G vs. A; OR=1.09, 95% CI: 0.80-1.48 for GG vs. AA; OR=0.95, 95% CI: 0.82-1.11 for AG vs. AA; OR=0.97, 95% CI: 0.84-1.13 for (AG+GG) vs. AA; and OR=1.09, 95% CI: 0.80-1.48 for GG vs. (AG+AA)]. Therefore, the currently available evidence suggests that the MTRR rs1801394 polymorphism may increase the risk of meningioma, whereas the MTRR rs1801394 polymorphism is not associated with meningioma.
authors.affiliation: Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
authors.forename: Xian-Tao
authors.initials: XT
authors.lastname: Zeng
authors.affiliation: Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
authors.forename: Jun-Ti
authors.initials: JT
authors.lastname: Lu
authors.affiliation: Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
authors.forename: Xiang-Jun
authors.initials: XJ
authors.lastname: Tang
authors.affiliation: Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
authors.forename: Hong
authors.initials: H
authors.lastname: Weng
authors.affiliation: Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China ; Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
authors.forename: Jie
authors.initials: J
authors.lastname: Luo
keywords: meningioma; meta-analysis; methionine synthase; methionine synthase reductase; polymorphism
references.citation: Stat Med. 2002 Jun 15;21(11):1539-58
references.pmid: 12111919
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1195-202
references.pmid: 18483342
references.citation: Biochemistry. 2002 Nov 12;41(45):13378-85
references.pmid: 12416982
references.citation: J Neurosurg. 2003 Nov;99(5):848-53
references.pmid: 14609164
references.citation: Eur J Hum Genet. 2010 Mar;18(3):370-8
references.pmid: 19826453
references.citation: Int J Cancer. 2006 Sep 1;119(5):1152-7
references.pmid: 16570277
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Blood. 2001 May 15;97(10):3205-9
references.pmid: 11342450
references.citation: Neuro Oncol. 2010 Jun;12(6):520-7
references.pmid: 20511189
references.citation: J Neurooncol. 2007 May;82(3):229-37
references.pmid: 17151932
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):969-76
references.pmid: 15824172
references.citation: N Engl J Med. 2001 Jan 11;344(2):79-86
references.pmid: 11150357
references.citation: Neurology. 2002 Jun 25;58(12):1849-52
references.pmid: 12084890
references.citation: J Natl Cancer Inst. 1980 Jul;65(1):67-73
references.pmid: 6930521
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Tumour Biol. 2013 Dec;34(6):3457-64
references.pmid: 23846816
references.citation: Am J Epidemiol. 2006 Oct 1;164(7):629-36
references.pmid: 16835295
references.citation: J Natl Cancer Inst. 2001 Feb 7;93(3):203-7
references.pmid: 11158188
references.citation: N Engl J Med. 1988 Oct 20;319(16):1033-9
references.pmid: 3173432
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1784-90
references.pmid: 16030117
references.citation: JAMA. 2007 Mar 21;297(11):1207-15
references.pmid: 17374815
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1655-61
references.pmid: 17684142
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2663-70
references.pmid: 18843008
references.citation: J Clin Oncol. 2008 Jan 10;26(2):279-82
references.pmid: 18182668
references.citation: Cancer. 2007 Jan 15;109(2):300-5
references.pmid: 17154163
references.citation: J Neurooncol. 2013 Nov;115(2):233-9
references.pmid: 23959833
references.citation: JAMA. 2000 Apr 19;283(15):2008-12
references.pmid: 10789670
references.citation: J Neurooncol. 2010 Sep;99(3):307-14
references.pmid: 20821343
references.citation: J Natl Cancer Inst. 2002 Oct 16;94(20):1555-63
references.pmid: 12381708
references.citation: J Neurosurg. 2008 May;108(5):999-1004
references.pmid: 18447718